ALT · XBRL financial data

Altimmune financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	4,410	(68)	426	20	41
Revenue from contracts with customers	8,185	4,410	—	—	—	—
Research and development	49,774	74,541	70,538	65,799	82,226	66,432
General and administrative	13,209	15,413	17,134	18,137	20,966	28,098
Total operating expenses	62,984	101,324	87,672	96,355	103,192	94,530
Operating income (loss)	(54,799)	(96,914)	(87,740)	(95,929)	(103,172)	(94,489)
Interest income	323	203	2,870	7,351	8,074	7,541
Interest expense	9	6	8	35	9	1,636
Other income (expense)	24	(374)	(32)	166	48	(190)
Income tax expense (benefit)	(5,417)	—	(197)	—	—	(681)
Net income (loss)	(49,044)	(97,091)	(84,713)	(88,447)	(95,059)	(88,093)
Earnings per share, basic USD per share	(1.91)	(2.35)	(1.81)	(1.66)	(1.34)	(1.00)
Earnings per share, diluted USD per share	(1.91)	(2.35)	(1.81)	(1.66)	(1.34)	(1.00)
Weighted average shares, basic thousands of shares	25,637	41,283	46,926	53,247	71,003	88,104
Weighted average shares, diluted thousands of shares	25,637	41,283	46,926	53,247	71,003	88,104

Fiscal years (ALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	115,918	190,301	111,097	135,117	36,926	43,760
Short-term investments	100,006	—	73,783	62,698	94,965	229,696
Marketable securities	—	—	—	—	—	229,696
Prepaid and other current assets	1,927	7,953	5,358	6,917	2,204	2,957
Total current assets	230,257	204,126	192,813	209,626	137,254	278,192
Property and equipment, net	1,057	1,448	1,081	651	413	312
Right-of-use asset	904	798	596	363	1,639	1,425
Total assets	245,115	218,865	206,928	210,640	139,306	279,929
Accounts payable	612	2,034	4,804	2,070	211	2,717
Accrued liabilities	11,408	—	—	—	—	—
Total current liabilities	12,020	18,276	17,054	12,143	10,468	14,997
Long-term debt	1,828	1,454	4,581	—	—	34,287
Lease liability, non-current	1,468	1,124	672	175	1,402	1,145
Total liabilities	19,239	19,730	21,635	16,541	15,798	55,037
Accumulated deficit	(186,421)	(293,171)	(377,884)	(466,331)	(561,390)	(649,483)
Total stockholders' equity	225,876	199,135	185,293	194,099	123,508	224,892
Total liabilities and equity	245,115	218,865	206,928	210,640	139,306	279,929
Common shares outstanding (cover page) thousands of shares	37,150	43,223	49,279	70,895	77,014	130,070

Fiscal years (ALT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(49,044)	(97,091)	(84,713)	(88,447)	(95,059)	(88,093)
Stock-based compensation	2,576	5,519	8,101	10,640	14,393	16,076
Depreciation and amortization	298	551	—	—	—	—
Net cash from operating activities	(34,437)	(78,238)	(62,586)	(75,810)	(79,848)	(67,535)
Purchases of property and equipment	204	12,117	126	47	—	11
Net cash from investing activities	(72,095)	87,523	(73,399)	13,732	(28,386)	(132,473)
Proceeds from issuing common stock	48,156	64,815	56,166	86,601	9,994	173,733
Proceeds from long-term debt	—	—	—	—	—	35,000
Net cash from financing activities	213,487	65,098	56,781	86,105	10,044	206,842
Net change in cash	106,955	74,383	(79,204)	24,027	(98,190)	6,834

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Altimmune	63,008	not reported	(24,221)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288,193	1,010	(25,049)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	168,560	223,273	23,319*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Rigel Pharmaceuticals	60,816	78,703	30,653*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	67,836	not reported	(32,501)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	156,512	39,550	9,223*	not reported	—	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39,267	10,131	(75,770)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Northwest Biotherapeutics	595	807	(7,169)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	175,700	110,000	100,100*	51.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.